Entera Bio Past Earnings Performance
Past criteria checks 0/6
Entera Bio's earnings have been declining at an average annual rate of -0.09%, while the Biotechs industry saw earnings growing at 11.8% annually. Revenues have been declining at an average rate of 29.5% per year.
Key information
-0.09%
Earnings growth rate
23.5%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -29.5% |
| Return on equity | -98.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Entera Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -9 | 4 | 4 |
| 31 Dec 23 | 0 | -9 | 4 | 5 |
| 30 Sep 23 | 0 | -10 | 6 | 5 |
| 30 Jun 23 | 0 | -11 | 6 | 5 |
| 31 Mar 23 | 0 | -11 | 7 | 5 |
| 31 Dec 22 | 0 | -13 | 8 | 6 |
| 30 Sep 22 | 0 | -14 | 7 | 7 |
| 30 Jun 22 | 0 | -14 | 7 | 8 |
| 31 Mar 22 | 0 | -14 | 7 | 7 |
| 31 Dec 21 | 1 | -12 | 6 | 7 |
| 30 Sep 21 | 1 | -12 | 5 | 5 |
| 30 Jun 21 | 1 | -10 | 5 | 5 |
| 31 Mar 21 | 0 | -11 | 5 | 6 |
| 31 Dec 20 | 0 | -11 | 5 | 6 |
| 30 Sep 20 | 0 | -11 | 5 | 7 |
| 30 Jun 20 | 0 | -13 | 5 | 7 |
| 31 Mar 20 | 0 | -11 | 5 | 7 |
| 31 Dec 19 | 0 | -11 | 4 | 7 |
| 30 Sep 19 | 1 | -10 | 4 | 7 |
| 30 Jun 19 | 1 | -12 | 4 | 7 |
| 31 Mar 19 | 1 | -9 | 3 | 8 |
| 31 Dec 18 | 1 | -10 | 3 | 9 |
| 30 Sep 18 | 0 | -11 | 5 | 8 |
| 30 Jun 18 | 0 | -10 | 7 | 6 |
| 31 Mar 18 | 0 | -13 | 8 | 5 |
| 31 Dec 17 | 0 | -11 | 9 | 3 |
| 30 Sep 17 | 0 | -8 | 6 | 2 |
| 30 Jun 17 | 0 | -6 | 4 | 3 |
| 31 Mar 17 | 0 | -4 | 3 | 3 |
| 31 Dec 16 | 0 | -1 | 3 | 3 |
Quality Earnings: 5DT is currently unprofitable.
Growing Profit Margin: 5DT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5DT is unprofitable, and losses have increased over the past 5 years at a rate of 0.09% per year.
Accelerating Growth: Unable to compare 5DT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5DT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.9%).
Return on Equity
High ROE: 5DT has a negative Return on Equity (-98.34%), as it is currently unprofitable.